Related Experiment Video
Updated: Feb 10, 2026

A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
Published on: June 15, 2011
Complex interactions in a novel SCN5A compound mutation associated with long QT and Brugada syndrome: Implications
Jie Liu1, Jason D Bayer2,3, Roozbeh Aschar-Sobbi1
1Department of Biology, York University, Toronto, Ontario, Canada.
Background:
The SCN5A mutation, P1332L, is linked to a malignant form of congenital long QT syndrome, type 3 (LQT3), and affected patients are highly responsive to the Na+ channel blocking drug, mexiletine. In contrast, A647D is an atypical SCN5A mutation causing Brugada syndrome. An asymptomatic male with both P1332L and A647D presented with varying P wave/QRS aberrancy and mild QTc prolongation which did not shorten measurably with mexiletine.
Objective:
We characterized the biophysical properties of P1332L, A647D and wild-type (WT) Na+ channels as well as their combinations in order to understand our proband's phenotype and to guide mexilitine therapy.
Methods:
Na+ channel biophysics and mexilitine-binding kinetics were assessed using heterologous expression studies in CHO-K1 cells and human ventricular myocyte modeling.
Results:
Compared to WT, P1332L channels displayed a hyperpolarizing shift in inactivation, slower inactivation and prominent late Na+ currents (INa). While A647D had no effect on the biophysical properties of INa, it reduced peak and late INa density when co-expressed with either WT or P1332L. Additionally, while P1332L channels had greater sensitivity to block by mexiletine compared to WT, this was reduced in the presence of A647D. Modelling studies revealed that mixing P1332L with A647D channels, action potential durations were shortened compared to P1332L, while peak INa was reduced compared to either A647D coexpressing with WT or WT alone.
Conclusions:
While A647D mitigates the lethal LQT3 phenotype seen with P1332L, it also reduces mexilitine sensitivity and decreases INa density. These results explain our proband's mild repolarization abnormality and prominent conduction defect in the atria and ventricles, but also suggest that expression of P1332L with A647D yields a novel disease phenotype for which mexiletine pharmacotherapy is no longer suitable.
Insights
The SCN5A P1332L mutation causes long QT syndrome, but the A647D mutation alters its presentation and reduces mexiletine effectiveness. This dual mutation creates a new phenotype where mexiletine is not a suitable treatment.
Area of Science:
- Cardiovascular Genetics
- Molecular Cardiology
- Ion Channel Physiology
Background:
- The SCN5A P1332L mutation is associated with congenital long QT syndrome type 3 (LQT3), typically responsive to mexiletine.
- The SCN5A A647D mutation causes Brugada syndrome.
- A patient with both mutations presented with atypical symptoms and lacked response to mexiletine.
Observation:
- Investigated the biophysical properties of SCN5A P1332L and A647D mutations, individually and combined, using heterologous expression and myocyte modeling.
- Assessed the impact of these mutations on sodium channel (Na+) function and mexiletine binding kinetics.
Findings:
- P1332L channels exhibited altered inactivation and increased late Na+ currents (INa).
- A647D reduced Na+ current density and mexiletine sensitivity when co-expressed with P1332L.
- Modeling indicated that the combined mutations result in shortened action potential durations and reduced peak INa compared to individual mutations.
Implications:
- The A647D mutation can mitigate the LQT3 phenotype but also reduces mexiletine efficacy.
- The co-expression of P1332L and A647D creates a novel cardiac phenotype with conduction defects.
- Mexiletine is not a suitable pharmacotherapy for patients with this combined SCN5A mutation profile.
Related Concept Videos
Mutations
Psychosis: Goals of Pharmacotherapy
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Local Anesthetics: Clinical Application as Surface, Infiltration, and Conduction Block Anesthesia
Coordination Compounds and Nomenclature
Viral Mutations

